Development of a novel vaccine for a viral pathogen

We are seeking to be part of a consortium as a partner. In this consortium, we can contribute the production of batches of an Investigational Medicinal Product under GMP standards in the EU, as a novel vaccine for a specific viral pathogen. ADVAXIA, formerly known as Advent, is a SME established in 2010 and situated near Rome, Italy. ADVAXIA has track record in producing clinical lots of adenoviral vectors as novel vaccines for many viral pathogens with epidemic/pandemic potential, including RSV, Ebola, HIV, HCV, HBV, RVF and SARS-CoV-2. We have expertise in the construction, rescue, and production of research-grade recombinant vectors, preclinical process development and scale-up, analytical development and validation, GMP manufacturing, GMP quality control, stability studies, QP release, and comprehensive support in quality assurance and regulatory affairs. ADVAXIA holds the latest GMP certificates, No: IT/77/H/2024 and IT-API/198/H/2024. We are GMP authorized to produce Active Pharmaceutical Ingredients (API) and Investigational Medicinal Products (IMP).